ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Anti-Obesity Medications and Investigational Agents
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 240760" data-attributes="member: 13851"><p><strong>Fig. 3b. <u>Glucose-dependent insulinotropic polypeptide (GIP; previously known as a gastric inhibitory peptide)</u>. GIP is an incretin. Its incretin effect is impaired in patients with type 2 diabetes mellitus. Combination glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GIP RA are in development and are illustrated by tirzepatide (Table 7 and Chart 3). [148–155]. DPP IV: Dipeptidyl Peptidase IV. * Unless combined with GLP-1, it is unclear that GIP receptor agonism alone reduces hunger and reduces body fat. However, GIP may enhance some of the effects of GLP-1 receptor agonism. The anti-nausea effects of GIP agonism may reduce nausea and adverse experiences described with GLP-1 receptor agonists [156, 147]. ** In patients without diabetes, GIP increases insulin secretion and enhances the deposition of fat in adipose tissues. In patients with diabetes mellitus, GIP may lose its insulinotropic effect, but retain a stimulatory effect on glucagon secretion – potentially worsening glucose levels [157]. However, as before, GIP receptor agonists may enhance some of the favorable effects of GLP-1 receptor agonists when administered concomitantly.</strong></p><p><strong>[ATTACH=full]27620[/ATTACH]</strong></p></blockquote><p></p>
[QUOTE="madman, post: 240760, member: 13851"] [B]Fig. 3b. [U]Glucose-dependent insulinotropic polypeptide (GIP; previously known as a gastric inhibitory peptide)[/U]. GIP is an incretin. Its incretin effect is impaired in patients with type 2 diabetes mellitus. Combination glucagon-like peptide-1 receptor agonist (GLP-1 RA) and GIP RA are in development and are illustrated by tirzepatide (Table 7 and Chart 3). [148–155]. DPP IV: Dipeptidyl Peptidase IV. * Unless combined with GLP-1, it is unclear that GIP receptor agonism alone reduces hunger and reduces body fat. However, GIP may enhance some of the effects of GLP-1 receptor agonism. The anti-nausea effects of GIP agonism may reduce nausea and adverse experiences described with GLP-1 receptor agonists [156, 147]. ** In patients without diabetes, GIP increases insulin secretion and enhances the deposition of fat in adipose tissues. In patients with diabetes mellitus, GIP may lose its insulinotropic effect, but retain a stimulatory effect on glucagon secretion – potentially worsening glucose levels [157]. However, as before, GIP receptor agonists may enhance some of the favorable effects of GLP-1 receptor agonists when administered concomitantly. [ATTACH type="full"]27620[/ATTACH][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Anti-Obesity Medications and Investigational Agents
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top